Do you want to read an article? Please log in or register.
Therapeutic cannabinoids in multiple sclerosis: immunomodulation revisited
Multiple Sclerosis
Related content
RECOMMENDED
Multiple Sclerosis
Advances in oral immunomodulating therapies in relapsing multiple sclerosis
★ 3
Recommended by
Prof. Dr Christian Kamm, Faculty Member
★ 2
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Lancet Neurol.
Derfuss T, Mehling M, Papadopoulou A, Bar-Or A, Cohen JA, Kappos L
doi: 10.1016/S1474-4422(19)30391-6.
RECOMMENDED
Multiple Sclerosis
Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis
Drug Saf.
Soleimani B, Murray K, Hunt D
doi: 10.1007/s40264-019-
Multiple Sclerosis
Progressive multiple sclerosis: from pathogenic mechanisms to treatment
Brain.
Correale J, Gaitán MI, Ysrraelit MC, Fiol MP
doi: 10.1093/brain/aww258.
Multiple Sclerosis
Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study.
J Neurol.
Kamm CP, Barin L, Gobbi C, Pot C, Calabrese P, Salmen A, Achtnichts L, Kesselring J, Puhan MA, von Wyl V, Swiss Multiple Sclerosis Registry (SMSR).
doi: 10.1007/s00415-019-09563-y.
SPECIAL REPORT
Multiple Sclerosis
Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis
Multiple Sclerosis
Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX®) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials
Medicines (Basel).
Turri M, Teatini F, Donato F, Zanette G, Tugnoli V, Deotto L, Bonetti B, Squintani G
doi: 10.3390/medicines5030059.
Multiple Sclerosis
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Ther Adv Neurol Disord
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F, ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG).
doi: 10.1177/17562864211039648
RECOMMENDED
Multiple Sclerosis
Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety
★ 2
Recommended by
Prof. Dr Christian Kamm, Faculty Member
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Drug Saf.
Giovannoni G, Galazka A, Schick R, Leist T, Comi G, Montalban X, Damian D, Dangond F, Cook S
doi: 10.1007/s40264-020-00948-x.
ECTRIMS 2019
Multiple Sclerosis